Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease

被引：21
作者：
Gan, Li [1 ]
机构：
[1] Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA
来源：
DRUG NEWS & PERSPECTIVES | 2007年 / 20卷 / 04期
关键词：
NF-KAPPA-B; SIR2 HISTONE/PROTEIN DEACETYLASES; PROTEIN DEACETYLASES; CELL-SURVIVAL; LIFE-SPAN; TRANSCRIPTION FACTORS; CALORIE RESTRICTION; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL-FUNCTION; AMYLOID HYPOTHESIS;
D O I：
10.1358/dnp.2007.20.4.1101162
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Sirtuins, known as silent information regulators, are class III histone deacetylases (HDAC) that catalyze deacetylation reaction in an NAD(+)-dependent manner. Evolutionarily conserved from bacteria to humans, sirtuins regulate important cell functions by deacetylating histone and nonhistone targets. Activation of sirtuin extends lifespan and promotes longevity and healthy aging in a variety of species, potentially delaying the onset of age-related neurodegenerative disorders. In mammalian systems, sirtuin activators protect against axonal degeneration, poly-glutamine toxicity and microglia-mediated amyloid 0 toxicity, suggesting the potential therapeutic value of sirtuins in patients with neurodegenerative diseases, such as Alzheimer's disease. In this review, we discuss the potential role of the sirtuin pathway in modifying the pathogenic processes in Alzheimer's disease. (C) 2007 Prous Science. All rights reserved.
引用
收藏
页码：233 / 239
页数：7
相关论文
共 76 条
  • [1] Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration
    Araki, T
    Sasaki, Y
    Milbrandt, J
    [J]. SCIENCE, 2004, 305 (5686) : 1010 - 1013
  • [2] Structure of a Sir2 enzyme bound to an acetylated p53 peptide
    Avalos, JL
    Celic, I
    Muhammad, S
    Cosgrove, MS
    Boeke, JD
    Wolberger, C
    [J]. MOLECULAR CELL, 2002, 10 (03) : 523 - 535
  • [3] An accelerated assay for the identification of lifespan-extending interventions in Drosophila melanogaster
    Bauer, JH
    Goupil, S
    Garber, GB
    Helfand, SL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (35) : 12980 - 12985
  • [4] Therapeutic potential of resveratrol:: the in vivo evidence
    Baur, Joseph A.
    Sinclair, David A.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) : 493 - 506
  • [5] The Sir2 family of protein deacetylases
    Blander, G
    Guarente, L
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2004, 73 : 417 - 435
  • [6] Mechanism of human SIRT1 activation by resveratrol
    Borra, MT
    Smith, BC
    Denu, JM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (17) : 17187 - 17195
  • [7] NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES
    BRAAK, H
    BRAAK, E
    [J]. ACTA NEUROPATHOLOGICA, 1991, 82 (04) : 239 - 259
  • [8] Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
    Brunet, A
    Sweeney, LB
    Sturgill, JF
    Chua, KF
    Greer, PL
    Lin, YX
    Tran, H
    Ross, SE
    Mostoslavsky, R
    Cohen, HY
    Hu, LS
    Cheng, HL
    Jedrychowski, MP
    Gygi, SP
    Sinclair, DA
    Alt, FW
    Greenberg, ME
    [J]. SCIENCE, 2004, 303 (5666) : 2011 - 2015
  • [9] Diversity in the Sir2 family of protein deacetylases
    Buck, SW
    Gallo, CM
    Smith, JS
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 75 (06) : 939 - 950
  • [10] SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling
    Chen, J
    Zhou, YG
    Mueller-Steiner, S
    Chen, LF
    Kwon, H
    Yi, SL
    Mucke, L
    Li, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (48) : 40364 - 40374
12345678